Rhythm Biosciences (ASX:RHY): Interview with CEO Glenn Gilbert

October 5, 2021

RHY, Rhythm Biosciences


We spoke with Rhythm Biosciences’ CEO Glenn Gilbert about the clinical progress of the ColoSTAT blood test for colorectal cancer risk and its commercial prospects post-approval in various jurisdictions around the world.


Read our most recent article on RHY here